Outcomes in Patients With Chronic Renal Failure on Hemodialysis After Aortic Valve or Root Replacement

      The long-term survival and reoperation rate in chronic renal failure (CRF) on hemodialysis (HD) patients after aortic valve/root replacement (AVR/ARR) with a stentless bioprosthesis is unknown. From 1992–2015, 1941 patients underwent AVR/ARR with stentless valve for primary indications of aortic stenosis/insufficiency, root aneurysm, and acute type A aortic dissection, including 93 CRF-HD (64 new-onset postoperative HD, and 29 preoperative HD) and 1848 non-CRF-HD. Data was obtained from the STS database, retrospective chart review, administered surveys and national death index data. Compared to the non-CRF-HD group, the CRF-HD group had significantly higher incidence of diabetes mellitus (28 vs 18%), CAD (49 vs 38%), COPD (31 vs 16%), NYHA class IV (12 vs 4%), atrial fibrillation (24 vs 12%), and previous cardiac surgery (27 vs 16%). Postoperatively, CRF-HD group had a higher reoperation for bleeding (10 vs 4%), length of hospital stays (20 vs 7 days), and operative mortality (23 vs 2.3%), all p < 0.01. The odds ratio of CRF-HD for operative mortality was 8.97. The long-term survival was worse in CRF-HD group than that in non-CRF-HD group [8-year survival: 31% vs 70%, p < 0.0001]. The hazard ratio of CRF-HD for long-term mortality was 2.4. The 10-year cumulative reoperation rate for structural valve deterioration in the CRF-HD group was 6.0% vs 5.0% in the non-CRF-HD group, p = 0.74. Surgeons should consider poor short- and long-term outcomes of patients with high risk of being on dialysis when offering aortic valve/root replacement. Bioprosthesis could be a good option in this patient population.

      Graphical Abstract



      ARR (aortic root replacement), AVR (aortic valve replacement), CRF (chronic renal failure), CRF-HD (chronic renal failure on hemodialysis), ESRD (end stage renal disease), HD (hemodialysis), SVD (structural valve deterioration), TAVR (transcatheter aortic valve replacement)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. ACC/AHA guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease).
        J Am Coll Cardiol. 1998; 32: 1486-1588
        • Kaplon R.J.
        • Cosgrove 3rd, D.M.
        • Gillinov A.M.
        • et al.
        Cardiac valve replacement in patients on dialysis: influence of prosthesis on survival.
        Ann Thorac Surg. 2000; 70: 438-441
      2. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; ACC/AHA 2006 guidelines for the management of patients with valvular heart disease 2006;114:e84–e231.

        • Yang B.
        • Malik A.
        • Farhat L.
        • et al.
        Influence of age on longevity of a stentless aortic valve [published online ahead of print, 2019 Dec 23].
        Ann Thorac Surg. 2019; S00034975: 31903-31908
        • Saran R.
        • Robinson B.
        • Abbott K.C.
        • et al.
        US renal data system 2019 annual data report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2020; 75: A6-A7
        • Raggi P.
        • Boulay A.
        • Chasan-Taber S.
        • et al.
        Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?.
        J Am Coll Cardiol. 2002; 39: 695-701
        • Bianchi G.
        • Solinas M.
        • Bevilacqua S.
        • et al.
        Are bioprostheses associated with better outcome than mechanical valves in patients with chronic kidney disease requiring dialysis who undergo valve surgery?.
        Interact Cardiovasc Thorac Surg. 2012; 15: 473-483
        • Hori D.
        • Kusadokoro S.
        • Kitada Y.
        • et al.
        Prosthesis selection for aortic valve replacement in patients on hemodialysis.
        Gen Thorac Cardiovasc Surg. 2020; 68: 122-128
        • Herzog C.A.
        • Ma J.Z.
        • Collins A.J.
        Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified?.
        Circulation. 2002; 105: 1336-1341
        • Böning A.
        • Boedeker R.H.
        • Rosendahl U.P.
        • et al.
        Long-term results of mechanical and biological heart valves in dialysis and non-dialysis patients.
        Thorac Cardiovasc Surg. 2011; 59: 454-459
        • Aljohani S.
        • Alqahtani F.
        • Almustafa A.
        • et al.
        Trends and outcomes of aortic valve replacement in patients with end-stage renal disease on hemodialysis.
        Am J Cardiol. 2017; 120: 1626-1632
        • Hegazy Y.Y.
        • Rayan A.
        • Sodian R.
        • et al.
        Medtronic Freestyle aortic bioprosthesis: a potential option for haemodialysis patients†.
        Interact Cardiovasc Thorac Surg. 2016; 22: 459-464
        • Dalrymple L.S.
        • Katz R.
        • Kestenbaum B.
        • et al.
        The risk of infection-related hospitalization with decreased kidney function.
        Am J Kidney Dis. 2012; 59: 356-363
        • Tanaka K.
        • Tajima K.
        • Takami Y.
        • et al.
        Early and late outcomes of aortic valve replacement in dialysis patients.
        Ann Thorac Surg. 2010; 89: 65-70
        • Brinkman W.T.
        • Williams W.H.
        • Guyton R.A.
        • et al.
        Valve replacement in patients on chronic renal dialysis: implications for valve prosthesis selection.
        Ann Thorac Surg. 2002; 74: 37-42
        • Nakatsu T.
        • Minakata K.
        • Tanaka S.
        • et al.
        Intermediate-term outcomes of aortic valve replacement with bioprosthetic or mechanical valves in patients on hemodialysis [published correction appears in J Thorac Cardiovasc Surg. 2020 Jan 7;:].
        J Thorac Cardiovasc Surg. 2019; 157: 2177-2186.e3
        • Khan M.Z.
        • Khan M.U.
        • Kalra A.
        • et al.
        Transcatheter versus surgical aortic valve replacement in patients with end stage renal disease.
        Catheter Cardiovasc Interv. 2020; : 1-8
      3. Centers for Disease Control and Prevention; National Center for Health Statistics. National Death Index n.d. 2018

      Linked Article

      • Commentary: Outcomes of Surgical Aortic Valve or Root Replacement in Patients on Hemodialysis: Lessons Learned and Remaining Challenges
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          End-stage renal disease (ESRD) patients undergoing hemodialysis (HD) are at high-risk when undergoing surgical aortic valve replacement (SAVR). After SAVR, the cardiovascular disease and renal comorbidities in these HD patients increase the risk of 30-day mortality by up to 15-17%, approximately 40% at 3 years, and 60% at 5 years.1–3 Thus, it is essential to carefully assess preoperative comorbidities of each patient and to optimize prosthetic valve selection and surgical procedure. This will minimize the deleterious effect of cardiopulmonary bypass (CPB) and HD-associated postoperative morbidities and increase survival and quality of life.
        • Full-Text
        • PDF
      • Commentary: Stentless AVR in dialysis patients – another hand on the elephant
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          There is a parable from the Indian subcontinent that a group of blind men approach an elephant and each of them has a dramatically different appreciation depending on which part of the elephant they are touching (tusk, ear, tail, trunk etc.). In the present report the authors make a valiant effort to understand the performance of the Medtronic Freestyle heterograft (Medtronic, Minneapolis MN) in the setting of Hemodialysis (HD) patients at their center and found excellent durability.1 Anecdotally, at our center we have also found the Freestyle valve a durable option for root replacement; and a recent review of Medicare recipients undergoing root replacement found excellent mid-term results.
        • Full-Text
        • PDF